-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Vaccination against SARS-CoV-2 is the main means to control the Covid-19 pandemic.
A particularly noteworthy safety signal related to the use of the ChAdOx1 novel coronavirus -19 vaccine (AstraZeneca) was recently reported, involving abnormal clinical coagulation abnormalities, especially cerebral venous thrombosis and thrombocytopenia, which in some cases caused death.
Thrombosis Management
The study reported 23 patients with thrombosis and thrombocytopenia 6 to 24 days after the first vaccination of ChAdOx1nCoV-19 vaccine (AstraZeneca).
immunity
Vaccination of SARS-CoV-2 vaccine is still the key to controlling the epidemic of new coronary pneumonia .
Coronavirus disease
The figure shows the flow cytometry analysis of the results of functional heparin-induced thrombocytopenia (HIT).
The figure shows the flow cytometry analysis of the results of functional heparin-induced thrombocytopenia (HIT).
An algorithm for the detection and treatment of patients with thrombosis and thrombocytopenia 5-30 days after vaccination.
An algorithm for the detection and treatment of patients with thrombosis and thrombocytopenia 5-30 days after vaccination.
In all cases reported so far, this thrombocytopenia and venous thrombosis syndrome appears to be triggered by receiving the first dose of the ChAdOx1 novel coronavirus -19 vaccine .
This thrombocytopenia and venous thrombosis syndrome appears to be a diagnostic infection triggered by receiving the first dose of ChAdOx1 novel coronavirus-19 vaccine
The risk of Covid-19 is still an important consideration for global public health.
Original source:
Scully Marie,Singh Deepak,Lown Robert et al.
Scully Marie,Singh Deepak,Lown Robert et al.
Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination.
[J] .
N Engl J Med, 2021, undefined: undefined.
Leave a message here
